Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04001920
Other study ID # 2013-008
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date July 23, 2013
Est. completion date December 13, 2013

Study information

Verified date June 2019
Source Université de Sherbrooke
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A strength and endurance training program was conducted in adults with myotonic dystrophy type 1 (DM1). Participants underwent a 12-week/18-session supervised training program consisted of 6 exercises: elbow flexion/extension, shoulder horizontal adduction, leg press, and knee flexion/extension. To offer a complete training program aimed at improving function it was divided: the first 6 weeks were dedicated to strength-training, whereas the following weeks focused on endurance-training. To evaluate the effects of the training program, participants completed maximal strength, endurance and functional evaluations. Volunteers could also add a muscle biopsy at the beginning and the end of the program to evaluate physiological parameters.


Recruitment information / eligibility

Status Completed
Enrollment 11
Est. completion date December 13, 2013
Est. primary completion date December 13, 2013
Accepts healthy volunteers No
Gender All
Age group 20 Years to 60 Years
Eligibility Inclusion Criteria:

- Adults with DM1

- Walk without technical aid

- Muscle impairment rating scale (MIRS) of 3 or 4

Exclusion Criteria:

- Severe musculoskeletal disorders

- Any medical contraindication to physical exercise

- Any medical contraindication to muscle biopsies for the biopsy volunteers

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Training program
12-week, 18-session training program. To offer a complete training program aimed at improving function it was divided : the first 6 weeks were dedicated to strength-training (2 sets of 6 repetitions at 80% of 1-RM), whereas the following weeks focused on endurance-training (1 set of 25 repetitions at 40% of 1-RM).

Locations

Country Name City State
Canada Groupe de recherche interdisciplinaire sur les maladies neuromusculaires Saguenay Quebec

Sponsors (2)

Lead Sponsor Collaborator
Cynthia Gagnon Fondation du Grand défi Pierre Lavoie

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in maximal muscle strength in the knee extensors measured by quantified muscle testing Changes in knee extensor maximal muscle strength evaluated by quantified muscle testing with a handheld dynamometer. Before and after the 12-week training program
Secondary Change in 6 minute walking test disance Walking endurance change measured by the 6 minute walking test distance. Before and after the 12-week training program
Secondary Changes in functional capacity measured by the UQAM-YMCA test Functional capacity evaluated by 18 functional tests Before and after the 12-week training program
Secondary Changes in sprint capacity measured by the Running-base anaerobic sprint test Sprint capacity changes measured by the running-base anaerobic sprint test Before and after the 12-week training program
Secondary Changes in fatigue measured by the Fatigue severity scale Fatigue questionnaire: 9-item questionnaire rated on a scale from 1 to 7 for each item. A score a higher score means more fatigue. Before and after the 12-week training program
Secondary Changes in daytime sleepiness measured by the Daytime sleepiness scale (Epworth Sleepiness Scale) 8-item questionnaire, rated on a scale from 0 to 3 for each item, the higher the score, the more the patient has daytime sleepiness. Before and after the 12-week training program
Secondary Changes in stumbles and falls measured by the Falls efficacy scale 10-item questionnaire about stumbles and falls. All items are rated on a 10-point scale. A higher score means a higher fear of falling. A score over 70 means a significant fear of falling. Before and after the 12-week training program
Secondary Changes in quality of life measured by the 36-Item Short Form Survey (SF-36) 36-item quality of life questionnaire. The final score is calculated on a total of 100 where the lower the score, the more disability. A score of 100 means no disability. Before and after the 12-week training program
Secondary Changes in life habits measured by questionnaire Life habits questionnaire Assessment of life habits is a 77-item questionnaire with a scale from 0 to 9 for each item. A higher score means no disability and a low score means more disability. Before and after the 12-week training program
Secondary Changes in muscle biopsy-muscle fiber size To assess changes in muscle fiber size Before and after the 12-week training program for volunteers
Secondary Changes in muscle biopsy-muscle fiber typing To assess changes in muscle fiber typing Before and after the 12-week training program for volunteers
Secondary Changes in muscle biopsy-proportion of centrally nuclated fibers To assess changes in muscle centrally nucleated fibers proportion Before and after the 12-week training program for volunteers
Secondary Changes in muscle biopsy-leucocyte infiltration To assess changes in muscle fiber leucocyte infiltration Before and after the 12-week training program for volunteers
See also
  Status Clinical Trial Phase
Recruiting NCT02880735 - Ventilatory Response After Non Invasive Ventilation in Type 1 Myotonic Dystrophy N/A
Recruiting NCT06378216 - Myotonic Dystrophy Type 1 Congenital and Juvenile Form: From Diagnosis to Rehabilitation [MDCJ-NeuBeRe]
Active, not recruiting NCT06089018 - Observational Study of Digital Biomarkers of Myotonia and Gait in Adults and Children With Myotonic Dystrophy
Completed NCT05662150 - Low-frequency Repetitive Nerve Stimulation in Myotonic Dystrophy Type 1 N/A
Active, not recruiting NCT04698551 - NIPD on cffDNA for Triplet Repeat Diseases
Completed NCT05027269 - Study of AOC 1001 in Adult Myotonic Dystrophy Type 1 (DM1) Patients Phase 1/Phase 2
Completed NCT04712422 - Poor Neck Proprioception May Cause Balance Deficits in Myotonic Dystrophy 1
Recruiting NCT05006924 - Symptoms and Outcome Measures for Upper- Limb Function in Myotonic Dystrophy Type 1
Recruiting NCT04656210 - Myotonic Dystrophy - Vascular and Cognition
Completed NCT04634682 - Effect of MYODM on Quality of Life, Fatigue and Hypersomnia in Patients With Myotonic Dystrophy Type 1 N/A
Withdrawn NCT06270186 - Evaluation of Cognitive Functions in 20 Patients With Type 1 Myotonic Dystrophy With Virtual Reality Approach N/A
Recruiting NCT06411288 - Global Study of Del-desiran for the Treatment of DM1 Phase 3
Recruiting NCT06300307 - Study of ATX-01 in Participants With DM1 Phase 1/Phase 2
Completed NCT02729597 - Tracking the Brain in Myotonic Dystrophies: a 5-year Longitudinal Follow-up Study N/A
Recruiting NCT06138743 - Study of ARO-DM1 in Subjects With Type 1 Myotonic Dystrophy Phase 1
Not yet recruiting NCT05532813 - Evaluation of the Efficacy and Safety of Metformin in the Myotonic Dystrophy Type 1 (Steinert's Disease) Phase 3
Active, not recruiting NCT04886518 - Safety and Efficacy of Pitolisant on Excessive Daytime Sleepiness and Other Non-Muscular Symptoms in Patients With Myotonic Dystrophy Type 1 Phase 2
Completed NCT05036447 - Myotonic Dystrophy Type 1 and Resistance Exercise N/A
Recruiting NCT03424460 - Venous Thromboembolism in Myotonic Dystrophy Type 1 N/A
Recruiting NCT05865483 - Profile of Dysphagia in Myotonic Dystrophy Type 1 (DM1)